Clinical Trial Update: Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Hu3S193 as consolidation therapy for women with ovarian, fallopian tube, or primary peritoneal cancer; the study is terminated and results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Hu3S193

Snippet

Sponsor: Recepta Biopharma | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-12-29